Bill & Melinda Gates Foundation

Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.

Tetragenetics, Inc. is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. Their technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease.

E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Immunocore is a focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.

VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.

Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.

Phase Genomics, Inc., a biotechnology company, develops technology for ProxiMeta Hi-C genome assemby and metagenome deconvolution. The company was founded in 2015 and is based in Seattle, Washington.

Flywheel Exchange LLC develops cloud scale data management platform for medical imaging core facilities, and academic and clinical research teams. The company offers tools, such as the flywheel web interface, a graphical user interface; the flywheel command line interface for uploading and downloading files, start jobs, and build gears; software development kits (SDK) for Python 2 and 3, Matlab, and R; and Flywheel Reaper for instrument integration. The company was incorporated in 2012 and is based in Minneapolis, Minnesota.

Picnic operates an online platform created to provide grocery supermarket services at low prices. It receives all the orders from users for the next day through its platform and sends them to bakers, greengrocers, and other suppliers. They deliver orders using electric vehicles, enabling consumers to order all of their groceries. Frederik Nieuwenhuys, Joris Beckers, and Michiel Muller co-founded it in Amsterdam-Duivendrecht, North Holland.

SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.The company's biotechnology platform develops bonding vaccines which are made from the proprietary protein superglue which is used to bond antigens to viruses and other particles to make vaccines, enabling medical institutions and research centers with a new and modified technology to develop vaccines which give better results in lesser time.

Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.

​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Northwest Evaluation Association (NWEA) is a not-for-profit organization committed to helping school districts throughout the nation improve learning for all students. NWEA partners with more than 2,200 school districts representing more than three million students. As a result of NWEA tests, educators can make informed decisions to promote your child’s academic growth.

Smart Immune is a clinical-stage biotechnology company focused on developing the next generation of hematopoietic stem cell-based biotherapies to change prognosis and life quality for patients with devastating diseases. The company first cell therapy program is based on T cell progenitors or ProTcellsTM (CD7+/CD34- ; CD5- cells) curative power to enable a short, polyclonal and safe post transplantation immune recovery. This program be completed by integrative developments from targeted conditioning to gene therapy and genome editing enabling clinicians to access new generation treatments for a wide variety of inherited blood disorders and blood cancers.

Ricult is a US-based award-winning Social Enterprise founded by MIT alums that enables farmers to pull themselves out of poverty while tapping a multi-billion dollar market. It has created an integrated digital platform that addresses the end to end needs of smallholder farmers in developing countries. Ricult currently operates in Thailand and Pakistan. Ricult is headquartered in Boston, MA, USA.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson’s disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

Vaxess Technologies, Inc., a biotechnology company, develops and commercializes silk biomaterial technologies. It offers MIMIX microneedle platform for transdermal delivery of vaccines and therapies; and MATRIX formulation and drying platform for the development of thermostable vaccine, therapeutic, and diagnostic products. The company was founded in 2011 and is based in Boston, Massachusetts.

Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

macro-eyes is a machine learning company that increases access to care

Quill (Empirical) is a nonprofit developer of free, interactive learning tools. Their mission is to make students active players in their education by presenting students with problems to solve and allowing them to construct solutions. In this environment students take charge of their own education. They support students, teachers, and parents. Teachers can sign up their classes and monitor their students' progress. They are currently working on parental accounts so that parents can receive report cards on their students' progress. They currently support middle school students studying English. They cover all of the grammatical concepts from the Common Core State Standards for grades 1-8. They intend to expand our coverage to high school students, college students, ESL students, SAT / ACT students, and foreign language students.

Full Investment Portfolio Cash and Short Term Investment fund: 23.59% Global Equity and Convertible Securities: 38.22% Government, mortgage and corporate debt fund: 8.60% Private equity: 6.12% Real Estate: 0.72% Infrastructure: 1.11% Return Hedge Fund: 17.91% Absolute Return fund: 3.74% Founded in 1924, the Scripps Research Institute is a non-profit organisation based in California, United States. The foundation focuses on research and education in the biomedical sciences.

Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com.

Biological Dynamics is an early-stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Their vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs. It was founded in 2008 and is headquartered in San Diego, California.

Hyperfine Research Inc. develops portable magnetic resonance imaging (MRI) scanners. The company’s MRI scanners are in areas of general anatomical brain imaging, headache, stroke, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Hyperfine Research Inc. was incorporated in 2014 and is based in Guilford, Connecticut.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.

Stellapps designs dairy management software applications that leverage the power of technology to improve dairy supply chain parameters. The company's applications leverage the Internet of Things (IoT), big data, cloud, mobility and data analytics to improve agri-supply chain parameters, including milk production, milk procurement, cold chain animal insurance and farmer payments, enabling dairy farms, dairy farmers and cooperatives to maximize profits while minimizing effort.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Loop Medical is on a mission to develop an easy and painless blood collection technology making it accessible to all. Loop Medical ensure blood collection fits into patients’ lifestyle while simplifying the process for the healthcare professionals. Loop collects blood samples in a proprietary cartridge that is fully compatible with standard laboratory processes. This venture is supported by Cerba Healthcare and the Bill and Melinda Gates Foundation.

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Uversity, Inc. develops student engagement software. It offers Schools App, an online community for colleges and universities that enables the users to engage future students with targeted, personalized messaging while gaining insight into their likelihood to enroll. The company also provides UChat, a chat widget for higher education to connect prospects with admissions professionals and student ambassadors. Uversity, Inc. was formerly known as Inigral, Inc. and changed its name to Uversity, Inc. in August 2013. The company was founded in 2007 and is based in San Francisco, California. As of July 8, 2015, Uversity, Inc. operates as a subsidiary of TargetX.com LLC.

MYDAWA is a new and innovative service that allows anyone buy wide range of high quality medication and wellness products affordably and conveniently from your mobile phone.

BudgIT is a creative agency meant develop a multi-platform a user friendly presentation of state and federal budget to include charts and performance analysis for proper understanding of what budgets entails. This is critical to benchmark governance and the government’s allocation to specific sectors. They clearly want to use their financial and technical expertise to make budgets understandable and deepen discussions around its allocation and expenditure as their contribution to citizenship participation.

In2Care BV provides mosquito control products. It offers mosquito traps that attracts and kills aedes vectors; bug shield sprays; and eave tubes to protect households and prevent malaria transmission. The company offers biological solutions to combat disease-carrying mosquitoes. It serves pest control operators through distributors in Central and South American countries, and the Caribbean. The company is based in Wageningen, the Netherlands.

All Raise is on a mission to accelerate the success of female founders and funders to build a more prosperous, equitable future. Born out of a grassroots movement in 2017, programs arm women with access, guidance, and support to advance their professional growth. The company was founded in 2017 by Stacey Bishop and Sarah Tavel and is based in San Francisco, California, United States.

Kaleidofin Private Limited owns and operates a financial technology platform that provides intuitive and tailored digital financial solutions to the informal sector. It offers goal-based financial solutions on savings, credit, investments, and insurance products to customers. The company provides products, such as umeed, that inculcates the savings habit for families with volatile income; lakshya, savings plan for 2 years and above; udaan, savings plan for long term goals; and kaleidoyantra, proprietary customer profiling algorithm. The company has partnership with banks, insurance companies, mutual fund houses, and technology companies. The company distributes its products through its mobile application, microfinance institutions (MFIs), co-operatives non-government organizations (NGOs), and self-help groups (SHGs). Kaleidofin Private Limited was incorporated in 2017 and is based in Chennai, India.

Enko Chem discovers and develops novel products for farmers to protect their crops from pests and diseases. Their proprietary technology platform represents a revolutionary approach to rapidly discover safe and economical solutions that are needed to ensure sustainable food production. It was founded in 2017 and headquartered in Woburn, Massachusetts.

Brightseed, Inc. develops Forager, a plant discovery platform that engages in discovery of molecules in plants that are clinically beneficial for chronic disease management. The company's platform then incorporates them back into the food supply chain, by using machine learning algorithms to screen plant genes and finding the best sources for each indication. Brightseed, Inc. was formerly known as Minotaur Bio, Inc. The company was founded in 2017 and is based in San Francisco, California.

Medsaf engages in delivering medications to hospitals, pharmacies, and clinics in Nigeria. It offers antacids, anaemia, antiviral, antineoplastics, antiseptics, probiotic, vaccine, and anesthetics drugs. In addition, the company also distributes vitamins and minerals supplements. It offers its products online. Medsaf was formerly known as Vitamins.ng. The company was founded in 2014 and is based in Lagos, Nigeria.

The Donald Danforth Plant Science Center is a not-for-profit research institute with a mission to improve the human condition through plant science. Scientists at the Danforth Center are engaged in research, which will contribute to feeding the hungry, improving human health, preserving and renewing the environment, and enhancing the St. Louis region and the State of Missouri as world centers for plant science

AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.

BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.

Avanti Platform is an open-access digital financial spine, flexible enough for users and partners to create, curate and deploy the financial products

Immunocore is a focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professional for a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests. The company empowers Indian consumers and caregivers to select the most appropriate healthcare service at the best possible price. 1mg was launched on 2015 and its operations are headquartered in Gurugram, India.

Cardea Bio Inc., a biotech company, develops, manufactures, and delivers commercial graphene-based digital biosensor hardware, software, and molecular infrastructure. The company focuses on creating products and applications that enable precision healthcare by improving diagnostic ease, speed, and cost. Its insight biosensors use the conductive and biocompatible nanomaterial graphene to convert biomolecules into digital elements enabling biology to connect directly to digital networks and creating access to biological data. The company was founded in 2013 and is headquartered in San Diego, California.

Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com.

Providence Therapeutics is a biotechnology company that develops a personalized mRNA cancer vaccine designed to treat advanced ovarian cancer. The company's vaccine identifies tumor mutations and elicits an immune response against the tumor cells, enabling users to treat themselves and live life to the fullest. It aims to provide safe and effective medicines for people suffering from diseases with unmet medical needs. Scott Leary, Eric Marcusson, and Bradley Sorenson established the company in Toronto, Ontario in 2015.

Nutreco is a global leader in animal nutrition and aquafeed. Our advanced nutritional solutions are at the origin of food for millions of consumers worldwide. Quality, innovation and sustainability are guiding principles, embedded in the Nutreco culture from research and raw material procurement to products and services for livestock farming and aquaculture. Experience across 100 years brings Nutreco a rich heritage of knowledge and expertise for building its future.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

Yemaachi Biotechnology uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies for lowering the economic burden of cancer.

Tetragenetics, Inc. is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. Their technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease.

Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.

Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well as agricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests.

Credence MedSystems is a drug delivery and specialty pharmaceutical company focused on delivering medications safely for the benefit of our patients, caregivers and partners. Credence MedSystems has changed the paradigm for drug manufacturers commercializing an injectable drug in a differentiated delivery system. The award-winning Companion Safety Syringe System combines a fully compliant, best-in-class injectable drug delivery system with a vastly simplified path to market for our pharma/biotech partners. This is called Innovation Without Change because we offer the innovation of the final device without the change that customarily accompanies combination product development.

Lumen helps educational institutions reduce textbook costs and improve student success using open educational resources and learning analytics. It creates affordable digital course materials using open educational resources (OER). Every Lumen OER course is designed to improve learning and replace expensive textbooks in high-enrollment college courses. Adding timely updates, learning design, and technical support to OER, Lumen makes the transition to open content simple, reliable, and effective for instructors and students. It was founded in 2013 and is headquartered in Portland, Oregon.

Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%. Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based on single-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture.

A bit of history: back in late 2009, a group of passionate, dedicated Philadelphia area educators – most of whom who had never met in person, but were connected by social media – somehow found themselves together at an unconference called Barcamp Philly. Despite the name, there was no alcohol and no camping (“Occupy” style or otherwise). There was, however, intense excitement as the event began, the day’s conference schedule was created before our eyes, and sessions got underway. By the end of the day, we’d all attended many workshops, led a few of our own, and collectively reached a powerful conclusion:

VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases.

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

Immunocore is a focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.

UW Medicine Health System is headquartered in the United States. UW Medicine Health System operates as a subsidiary of University of Washington.

VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.

A biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. It antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses.

Avanti Platform is an open-access digital financial spine, flexible enough for users and partners to create, curate and deploy the financial products

Avanti Platform is an open-access digital financial spine, flexible enough for users and partners to create, curate and deploy the financial products

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

Clayton County Public Schools is a public school district

Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.

Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to licence programmes early with a pharmaceutical partner for further development.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Atomwise Inc. is a deep learning AI technology for structure-based small molecule drug discovery. Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. Its speed and accuracy make it the most advanced technology for small molecule binding affinity prediction. AtomNet, its AI platform built for drug discovery contains more than 16 billion molecules for virtual screening.

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive patient monitoring products. It provides a patient monitoring solution that incorporates a monitor or circuit board and sensors, including both proprietary single-patient use and reusable sensors and cables. The company also offers Masimo Signal Extraction Technology, which provides the capabilities of measure-through motion and low perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. In addition, it provides remote-alarm/monitoring solutions and software. The company sells its products to end-users through direct sales force and distributors, as well as to original equipment manufacturers and partners to incorporate into their products. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.

Batavia Biosciences focuses on accelerating the transition of biopharmaceutical product candidates from discovery to the clinic with improved success and lower cost. Our services cover candidate selection, production of research materials, upstream and downstream process development, assay development, product characterization and clinical manufacturing and release. Batavia Biosciences has successfully worked on viral and bacterial vaccines, recombinant proteins, antibodies and gene therapy products. Unique technologies such as STEP® protein expression technology and SCOUT® high throughput process technology accelerate timelines and reduce costs.

Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com.

Ceres Nanosciences Inc. (“Ceres”) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology, which captures, enriches and preserves analytes/biomarkers. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres has a broad product pipeline of advanced sample collection technologies and diagnostics, funded through federal agency grants and industry collaboration funding. Ceres’ lead product in development is a direct antigen test for the diagnosis of Lyme disease, which will be available commercially in 2015.

IBM Global Services is a business and technology services provider. IBM Global Services was created in 1991 in order to help companies manage their IT operations and resources. IBM Global Services has two major divisions: Global Business Services (GBS) and Global Technology Services (GTS). IBM Global Services (U.S.) operates as a subsidiary of International Business Machines Corporation.

Uversity, Inc. develops student engagement software. It offers Schools App, an online community for colleges and universities that enables the users to engage future students with targeted, personalized messaging while gaining insight into their likelihood to enroll. The company also provides UChat, a chat widget for higher education to connect prospects with admissions professionals and student ambassadors. Uversity, Inc. was formerly known as Inigral, Inc. and changed its name to Uversity, Inc. in August 2013. The company was founded in 2007 and is based in San Francisco, California. As of July 8, 2015, Uversity, Inc. operates as a subsidiary of TargetX.com LLC.

The Sure Chill Company Ltd. provides cooling technology solutions using solar panels. It offers its systems for medical, food and beverage, and domestic refrigeration applications worldwide. The Sure Chill Company Ltd. was formerly known as True Energy Limited and changed its name to The Sure Chill Company Ltd. in April 2013. The company was incorporated in 2002 and is based in Tywyn, United Kingdom.

Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

Teller, based in the United States, is an artificial intelligence banking assistant that allows customers to communicate with banks through their favorite messaging platforms without needing to download a new app. Teller's chatbot can answer hundreds of financial questions, as well as provide advice on saving, budgeting, improving one's credit score, investing, and retirement. It also helps banks to automate the simple, repetitive questions that they receive, providing timely customer service.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

PnuVax Incorporated is dedicated to the production of high quality biopharmaceuticals for the promotion of public health worldwide. Their team has over 30 years of experience in the pharmaceutical industry, from research to full scale production.

Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.

ConnectEDU’s technology solutions empower learners by informing their academic and career decisions. By serving educators, students, parents, administrators, and employers, ConnectEDU helps progress learners and guide their transitions from school to career. Today, ConnectEDU serves more than 20 million registered learners; 5,000 educational institutions; and 130,000 employers throughout 40 countries. ConnectEdu, Inc. was founded in 2002 and is based in Boston, Massachusetts.

PowerMyLearning is a national non-profit that leverages technology to strengthen the learning relationships among students, teachers, and families so that all students can succeed. Our work fosters growth in teachers as instructional leaders; in families as support partners; and in students as learners who can meet the challenge of high academic standards.

Unigo’s consumer site has 1.8 million registered users and receives 14 million unique visitors per year. The site provides personalized matches with 6,500 colleges, 700,000 college reviews, 3.6 million scholarships, 90,000 internships and 3.3 million study materials. Unigo’s investors include McGraw-Hill Ventures, Dow Jones Ventures / News Corp, and The Gates Foundation. Unigo licenses college data and reviews to many mainstream media brands including The Wall Street Journal, U.S. News & World Report, USA Today, and ABC News. Unigo also created curriculum and tutoring services with McGraw-Hill Education taught in high schools across the country. At b2e.unigo.com, Unigo provides enrollment and market research services directly to colleges and universities. Each year, Unigo reaches more than 50% of all college-bound students and provides services to approximately 9 million consumers. The company has received awards and recognitions from Facebook, the Webby Awards, the White House, the Viacom / Get Schooled Foundation and more.

Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU is the kind of place where the big news doesn't always involve sports, politics, fashion or even weather. The big news is always about health — health care, health education, health-related research. And various organizations and publications that rank American institutions, programs and faculty in a variety of categories have taken note. Nearly one million patient visits each year. Educating thousands of future health care providers. You get the picture. Immerse yourself in more facts and stats than you probably need about Portland's largest employer, Oregon's provider of care to every corner of the state, and one of the nation's top 28 biomedical research institutions. Oregon Health & Science University is the state’s only academic health center. It provides an uncommon array of services from providing the state’s most comprehensive health care, to educating the next generation of clinicians and biomedical researchers, to achieving breakthroughs and innovations.

Logrado develops mobile solutions for higher education to increase and improve college access, student support, persistence and retention. Logrado received funding through the Bill & Melinda Gates Foundation's College Knowledge Challenge.

Boragen develops synthetic chemistry platforms designed to produce next-generation fungicides. The platform supports sustainable farming methods by creating a compound that decreases the probability of fungicide resistance and reduces the amount of chemical applied while maintaining performance and efficacy. The company utilizes boron’s unique properties to design and develop novel solutions targeting needs in crop protection, animal health, and human health. Founded in 2015, Boragen is based in Durham, North Carolina.

Founded in 2010, BloomBoard is leading the shift from professional development to educator advancement via micro-certification. The company partners with states and districts to enable a unique online learning experience where educators can improve their instructional practice and advance in their careers by earning micro-credentials. BloomBoard aims to help all organizations transition to meaningful, purpose-driven educator development and advancement based on measurable certification. For more information, visit bloomboard.com.

Acrobatiq, backed by Carnegie Mellon is scaling the pioneering research in online learning from CMU's Open Learning Initiative (OLI) and enabling educational institutions to improve learning outcomes at reduced costs through data-driven, personalized learning solutions. Our learning-science based approach to course design, and breakthrough analysis and modeling of learning data enables adaptive instruction for students, and gives faculty visibility into who is learning, who’s not, and where help is needed. Together, this convergence of learning science, technology, and data is empowering more students to succeed at a time when post-secondary credentials are more in demand than ever.

MedinCell is an injectable slow-release drug specialist company.

Montreal Heart Institute is a specialty hospital dedicated to the development of cardiology.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.

IDRI is a Seattle-based not-for-profit committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, we strive to create an efficient pathway to bring scientific innovation from the lab to the people who need it most.

Phase Genomics, Inc., a biotechnology company, develops technology for ProxiMeta Hi-C genome assemby and metagenome deconvolution. The company was founded in 2015 and is based in Seattle, Washington.

NASSCOM Foundation is a non-profit organization that is building an ecosystem to bring to fruition. It facilitates business responsibility, promotes ICT solutions for development, empowers NGOs with technology, and influences policy-making through thought leadership. NASSCOM Foundation was founded in 2001 and is based in New Delhi, India.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.

DelSiTech, Ltd. engages in developing and licensing long-term controlled drug delivery implants, subcutaneous, and intramuscular formulations. It offers silica-based implants, subcutaneous, and intra-muscular injectable technology for controlled release of small molecular drugs and biopharmaceuticals. The company’s drug delivery products inject proteins, polysaccharides, and viruses. DelSiTech, Ltd. was founded in 2001 and is based in Turku, Finland.

Apeel Technology, Inc., doing business as Apeel Sciences, develops pre-and post-harvest products from natural plant extracts to protect food crops and keep produce fresher for farmers worldwide. Its portfolio of agricultural products includes Edipeel, a solution to protect food surfaces from the environment; and Invisipeel, a solution that protects against pre-harvest problems. Apeel Technology, Inc. was formerly known as aPEEL Technologies, Inc. The company was founded in 2012 and is based in Goleta, California.

As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.

Vaxxas Pty. Ltd. develops and commercializes vaccine delivery technologies. It offers Nanopatch platform that induces immune system activation by targeting vaccine to the abundant immunological cells below the surface of the skin. Vaxxas Pty. Ltd. was incorporated in 2011 and is based in Sydney, Australia with an additional office location in Cambridge, Massachusetts.

Kymab Limited discovers, develops, and commercializes human therapeutic monoclonal antibodies for the treatment of human diseases using its proprietary Kymouse platform. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates human antibody-based biopharmaceuticals directed against clinically precedented drug targets and drugs against novel targets. The company was incorporated in 2009 and is based in Cambridge, the United Kingdom.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

BudgIT is a creative agency meant develop a multi-platform a user friendly presentation of state and federal budget to include charts and performance analysis for proper understanding of what budgets entails. This is critical to benchmark governance and the government’s allocation to specific sectors. They clearly want to use their financial and technical expertise to make budgets understandable and deepen discussions around its allocation and expenditure as their contribution to citizenship participation.

SurveyAuto has developed an advanced platform to collect reliable data from the field, especially in the developing countries. The platform combines recent advances in Artificial Intelligence (machine learning) with smartphone applications to collect high quality data. SurveyAuto uses machine learning on satellite imagery to accurately identify survey targets, tracks and monitors enumerators in real-time using smartphone applications, and uses speech and image analysis to automatically analyse the quality of collected data.

Treedom s.r.l. operates an online platform that allows users to plant or dedicate a tree online. Its platform allows users to choose a tree to plant it for them, follow it, and find out how much CO2 it emits every day, as well as gift trees. The company also allows businesses to plant trees in their brand names. Treedom s.r.l. was founded in 2010 and is based in Florence, Italy.

Sidai is a fully vertically-integrated company supplying quality livestock and crop inputs and training to farmers and pastoralists across Kenya. The company operates through a network of branded, professionally-staffed, company-managed and franchised retail outlets, stockists and field staff. Sidai has a unique ‘last-mile’ service delivery model that also reaches pastoralists and farmers in remote and under-served locations.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.

PiQuant provides component detecting sensor and device based on spectroscopy. - High Sensitivity : PiQuant sensor can detect up to molecular unit - Small Size : PiQuant provides a sensor the size of a thumb and a detecting device the size of a hand can hold - Affordable Price : PiQuant offers less than one-tenth of the price of a conventional sensor.

Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.

The Sure Chill Company Ltd. provides cooling technology solutions using solar panels. It offers its systems for medical, food and beverage, and domestic refrigeration applications worldwide. The Sure Chill Company Ltd. was formerly known as True Energy Limited and changed its name to The Sure Chill Company Ltd. in April 2013. The company was incorporated in 2002 and is based in Tywyn, United Kingdom.

Trade is a platform that connects buyers, sellers, and transporters of commodities in Ghana. Trade allows buyers and sellers in Ghana to trade directly, cutting out the middlemen. You pick your quantity, grade, and price and they look for sellers to match you with. They weigh and grade every bag that they trade, deliver directly to you, and will take back any bag you reject, so you can buy without worrying.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Techlets is a provider of a suite of products in the AI-driven MarTech (Marketing Technology). Core product is, Walee - an everyday trade app which enables businesses looking to sell online, and social influencers looking to work with businesses, connect, contract, collaborate and pay each other through an AI-driven matchmaking and financial services engine. Walee has Pakistan's largest and fastest growing influencer network.

Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well as agricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests.

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

Code.org is a non-profit foundation dedicated to growing computer programming education. Its vision is that computer science and computer programming are included in the core curriculum in U.S. education, alongside other STEM (science technology engineering math) courses, such as biology, physics, chemistry and math.

FirstBank introduces the Firstmonie Mobile Money Service, an innovative product that enables customers to access financial and other value added services through their mobile phones. This caters to the high percentage population of unbanked population across the country. According to Mr Bisi Onasanya, Group Managing Director, FirstBank, “with the inauguration of this service, the stage is now set for the bank’s customers and anyone in Nigeria with a mobile phone to enjoy financial services, using their mobile phones to send money, pay bills, top up their phone airtime, do shopping, deposit and withdraw cash, without the need to visit a bank branch.” He added that Firstmonie services were created with three principles in mind. “The first is defined by how consumers receive money to fund their unique lifestyles; how consumers spend money for their unique lifestyle needs; and thirdly, the ability of the consumer to be informed and in control of their money,” The service is available on all major the network telecommunications operators including MTN Nigeria, Etisalat and Globacom. FirstBank will also leverage on the fund transfer capability of the mobile telephony to offer world class services, noting that mobile phone has the capability to store monetary information and like other channels of e-banking, is closer and always with the customer.

Immunethep is a biotechnology company focused on drug development for Immune System related pathologies. Immunethep is a spin-off from the University of Porto that uses its proprietary technology to address unmet medical needs. Immunethep discovered a novel mechanism used by different pathogenic bacteria to suppress host immune response. By targeting this mechanism we are developing broad coverage anti-bacterial immunotherapies.

City Schools is committed to ensuring that all students graduate from high school ready for college, career training, and life success in the 21st century. This work, guided by priorities PDF icon set by the Baltimore City Board of School Commissioners, includes - Implementation of new curricula aligned to Maryland's College and Career-Ready Standards, incorporating the Common Core State Standards - Expansion of systems to ensure effective instruction and leadership across the district, including new evaluations for teachers and school leaders - Launch of the design phase for modern, high-quality school buildings under the 21st-Century Buildings Plan.

Novartis Animal Health is a leader in developing new and better ways to prevent and treat diseases in pets, farm animals and farmed fish. Their innovative, high-quality medicines contribute to the quality of life, health and welfare of animals around the world. They focus on developing new products and technologies to meet the diverse needs of pet owners, veterinarians, farmers and fish farmers now and in the future. Their scientists strive to improve animal care and welfare by researching new medicines and novel drug delivery technologies to improve efficacy and ease of use.

Biological Dynamics is an early-stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Their vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs. It was founded in 2008 and is headquartered in San Diego, California.

Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. The company offers AtomoRapid RDT platforms to suit various blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its rapid test devices are used by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection. The company has operations in Europe, Asia, Africa, and Central and South America. Atomo Diagnostics Limited was founded in 2010 and is headquartered in Leichhardt, Australia.

Kymab Limited discovers, develops, and commercializes human therapeutic monoclonal antibodies for the treatment of human diseases using its proprietary Kymouse platform. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates human antibody-based biopharmaceuticals directed against clinically precedented drug targets and drugs against novel targets. The company was incorporated in 2009 and is based in Cambridge, the United Kingdom.

International Partnership For Microbicides provides women with self-initiated HIV-prevention strategies they can use to protect their own health. It aims to prevent HIV transmission by accelerating the development and availability of safe and effective microbicides for use by women in developing countries. International Partnership For Microbicides focuses on developing antiretroviral based microbicides in collaboration with its partners. It was founded in 2002 as a product development partnership. International Partnership For Microbicides is headquartered in Silver Spring, Maryland.

Ricult is a US-based award-winning Social Enterprise founded by MIT alums that enables farmers to pull themselves out of poverty while tapping a multi-billion dollar market. It has created an integrated digital platform that addresses the end to end needs of smallholder farmers in developing countries. Ricult currently operates in Thailand and Pakistan. Ricult is headquartered in Boston, MA, USA.

macro-eyes is a machine learning company that increases access to care

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

M-KOPA Kenya Limited develops and markets solar home systems. It offers solar systems with three lights, phone charging, and a solar powered radio. The company sells its products through dealers and retail shops in Kenya. It offers M-KOPA 5, KOPA 6, KOPA 600, and KOPA 6000. M-KOPA Kenya Limited was founded in 2011 and is based in Nairobi, Kenya. M-KOPA Kenya Limited operates as a subsidiary of M-Kopa, LLC.

Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Jamii Africa is mobile micro-health insurance for the informal sector. They built a mobile policy management platform that performs 99% of insurance administration activities and formed strategic partnerships with an Insurer/ Jubilee Insurance and a Telecom/ Vodacom Tanzania to enable a cashless facility and utilise the mobile money platforms for premium collection and benefit payouts. Their platform manages the benefit ledger and is integrated to mobile money and insurer systems. Enabling us to cut down administration costs by 99% which results to cheaper premiums affordable to their target market.

M-KOPA Kenya Limited develops and markets solar home systems. It offers solar systems with three lights, phone charging, and a solar powered radio. The company sells its products through dealers and retail shops in Kenya. It offers M-KOPA 5, KOPA 6, KOPA 600, and KOPA 6000. M-KOPA Kenya Limited was founded in 2011 and is based in Nairobi, Kenya. M-KOPA Kenya Limited operates as a subsidiary of M-Kopa, LLC.

two quirky scientists vowed to make the world a better place. After learning their trades in some of the world’s biggest scientific organisations, Paul and Mark Davis (father and son team with a striking resemblance to Pinky and the Brain established Mologic to do as much good as possible in healthcare and education. They want to improve patient care and quality of life, and break new ground in exciting fields of research (unlike Pinky and the Brain who wanted to take over the world).

Thirty years ago, the women’s funding movement was a gathering of about 20 leaders who were convinced that philanthropy and social change needed to more fully recognize and include women’s voices. Learn more about their unique history and the efforts of women across centuries to spark greater investment in issues affecting women and girls. Today, Women’s Funding Network is a growing community of more than 160 women’s funds and foundations spanning 30 countries. Their latest annual report and impact reports share stories, data, and more about how their Network is making a difference locally, regionally, and globally. Serving this growing community is the task of a diverse team, including their talented staff and their Board of Directors comprised of member representatives, visionary supporters, and thought leaders from around the world. Will you join us in creating a movement of women-led change? Please consider making a gift or becoming a member today.

Centre for Innovation in Regulatory Science is a neutral, independently managed UK-based subsidiary company, forming part of the Clarivate Analytics group. CIRS provides an international forum for industry, regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and reimbursement policy through the innovative application of regulatory science and to facilitate access to medical products. This is CIRS’ purpose. CIRS is operated solely for promotion of its purpose. The organisation has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities, special projects and grants.

A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Kymab Limited discovers, develops, and commercializes human therapeutic monoclonal antibodies for the treatment of human diseases using its proprietary Kymouse platform. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates human antibody-based biopharmaceuticals directed against clinically precedented drug targets and drugs against novel targets. The company was incorporated in 2009 and is based in Cambridge, the United Kingdom.

Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

OneGoal offers that solution at a low cost and makes graduation a reality for all students. OneGoal collaborate closely with public schools in low-income communities, providing teachers with a robust curriculum, technology, training and coaching to implement our three-year model with a group of 25 students (Fellows) per cohort. Teachers support the same group of Fellows beginning in their junior year of high school and bridge the gap through their first year of their postsecondary education.

macro-eyes is a machine learning company that increases access to care

Uversity, Inc. develops student engagement software. It offers Schools App, an online community for colleges and universities that enables the users to engage future students with targeted, personalized messaging while gaining insight into their likelihood to enroll. The company also provides UChat, a chat widget for higher education to connect prospects with admissions professionals and student ambassadors. Uversity, Inc. was formerly known as Inigral, Inc. and changed its name to Uversity, Inc. in August 2013. The company was founded in 2007 and is based in San Francisco, California. As of July 8, 2015, Uversity, Inc. operates as a subsidiary of TargetX.com LLC.

Novavax is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Crane Engineering is a leading provider of high performance fluid systems solutions to a broad range of industries throughout the U.S., Canada and Mexico. Everything we do is about reducing your total cost of ownership and helping you make your fluid systems run better. For over 75 years we've had our customers' backs, providing them with fluid processing know-how and solutions specifically engineered for efficiency and profitability. Working with the world's top fluid technology manufacturers, we bring our customers innovative ideas that make a real difference in performance and help reduce total cost of ownership. At Crane Engineering, we've brought together the people, products, and experience to help you perform better. Leverage their abilities to make the Crane Advantage, your advantage.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Landcent accelerates the fight against global infectious diseases, by developing & delivering affordable, sustainable solutions, that are safe to use at scale.

As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

PT HaloDoc provides a communication platform that connects patients with doctors. It offers HaloDoc that enables users to connect with doctors through video calls, voice calls, and chat; order laboratory tests; and find the closest hospitals, clinics, and doctors. It also offers its service through its Website. PT HaloDoc was founded in 2016 and is based in Jakarta, Indonesia.

Full investment portfolio: Short-term investments and cash equivalents: 2.19% Public equity: 37.18% Absolute return/fixed income: 30.08% Private equity/venture capital: 21.57% Real assets: 8.83% Derivative instruments: 0.11% Joint ventures: 0.03% Founded in 1836, the Emory University is a non-profit organisation based in the United States. The foundation is a coeducational institution that owns and operates educational, research, and healthcare facilities along with providing educational services to undergraduates and graduates in arts and sciences and medicine.

Ventria Bioscience is a privately held biopharmaceutical company with a product pipeline enabled by ExpressTec. ExpressTec is a patented, plant-based recombinant protein manufacturing technology that delivers a ten-fold higher recombinant protein yield than other plant-based systems. Ventria Bioscience's platform technology delivers meaningful and sustainable economic advantages by enabling new product opportunities that were not previously available. It can be used to develop new biotherapeutics, novel vaccines, reagents for biomanufacturing, and industrial and biofuel enzymes.

GiveIndia operates as a most trustworthy giving platform for donors. With contributions of over 300 crores made to our 200+ vetted and trusted nonprofits, our giving community of 1M+ donors has impacted lives of 4M+ people across 23 states in India.

Sidai is a fully vertically-integrated company supplying quality livestock and crop inputs and training to farmers and pastoralists across Kenya. The company operates through a network of branded, professionally-staffed, company-managed and franchised retail outlets, stockists and field staff. Sidai has a unique ‘last-mile’ service delivery model that also reaches pastoralists and farmers in remote and under-served locations.

Loop Medical is on a mission to develop an easy and painless blood collection technology making it accessible to all. Loop Medical ensure blood collection fits into patients’ lifestyle while simplifying the process for the healthcare professionals. Loop collects blood samples in a proprietary cartridge that is fully compatible with standard laboratory processes. This venture is supported by Cerba Healthcare and the Bill and Melinda Gates Foundation.

Founded in 1781, Takeda Pharmaceutical Company Limited is a corporate firm based in Tokyo, Japan. The firm researches, develops and manufacture the pharmaceutical products.

RJH Biosciences focus on development of transfection reagents and delivery agents for nucleic acids. The company distributes its products via its website and undertakes projects on new medical treatments.

Pivot Bio, Inc. operates as a biotechnology company that provides genome-scale programming of microbes. The company was founded in 2010 and is based in Emeryville, California.

Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City. Recursion combines experimental biology, automation, and artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. Recursion is aggressively leveraging technology to build a robust and reliable map of human cellular biology, which will enable a radical shift in the pace and scale at which new treatments will benefit patients.

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease, cancer, and other metabolic conditions.

Making nature accessible and affordable for a growing society.It is estimated that the world’s population will increase by more than 35% by 2050, reaching 9 billion people. Crop production will need to more than double in order to feed these people and meet the consumer needs of a developing world. With very little land remaining for agricultural expansion, they as a society need to find ways to maximize the use of their world’s resources. Plants produce a variety of rare natural products which are used in their daily lives as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals and agricultural chemicals. They strive to reduce their dependence on land- and resource-intensive practices by recreating natural processes through biotechnology.

Affinivax, Inc., a biotechnology company, focuses on developing multiple antigen presenting system (MAPS) technology based vaccines that provide protection against various infectious diseases afflicting children and adults around the globe. Its MAPS enables the binding of protective polysaccharides and proteins in a single vaccine and induces a protective immune response. The company develops its vaccine programs to target various pathogens, such as streptococcus pneumoniae (pneumococcus), bacterial nosocomial infections, salmonella typhi, and staphylococcus aureus. Affinivax, Inc. was incorporated in 2014 and is based in Lexington, Massachusetts.

Tanda is a financial solutions platform that capitalizes on the need for alternative banking products in a region characterized with high financial exclusion. We currently offer a digitized ROSCA and are continuously adding new financial products to serve the financially un- and underserved adult population in the region, specifically women. Tanda believes that an overall lack of financial services that represents the nature of demand in the Arab World has led to the exclusion of many women in the Arab World from accessing financial services. By addressing that, we would give the previously un- and underserved women and vulnerable segments the ability to participate in the economy while consuming products that improve their financial health. Tanda aims to target the unbanked and underserved segments in an effort to provide a formal financial system designed to suit their needs and financial standing. This is important in the movement towards this segment having consolidated payment platforms.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

Evolve Biosystems is a biotechnology company that specializes in providing microbiome-based products designed to develop, restore, and maintain. The company's platform focuses on solving the gut dysbiosis throughout the human life cycle as well as in various animal species, enabling physicians to maintain the healthy gut microbiome in newborn infants with a consumer-directed home use product, and a hospital-based neonatal ICU product. It was founded in 2011 and headquartered in Davis, California.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

CropIn is a leading AI and Data-led agri-tech​ organization that provides SaaS solutions to agribusinesses globally. CropIn’s unique suite of products enables various stakeholders in the agri-ecosystem to adopt and drive digital strategy across their operations. Using cutting-edge technology like big data analytics, artificial intelligence, machine learning, and remote sensing, CropIn creates an interconnected network of all these stakeholders at different levels of the agriculture ecosystem, enabling clients to analyze and interpret data to derive real-time actionable insights on standing crop. Businesses can thus leverage technology to effectively drive their initiatives around Digitization, Predictability, Compliance, Sustainability and Traceability. With the vision to ‘maximize per acre value’ and the mission to ‘make every farm traceable’, CropIn adds value to agri-businesses by increasing efficiency, scaling productivity, and strengthening sustainability across the board. Thus far, CropIn has digitized over 5.5 million acres of farmland and enriched the lives of nearly 2.1 million farmers, while gathering data on 380+ crops and 3,600+ crop varieties in 46+ countries on 6 continents.

BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform. The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic “pivot” in 2016–17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.

Making nature accessible and affordable for a growing society.It is estimated that the world’s population will increase by more than 35% by 2050, reaching 9 billion people. Crop production will need to more than double in order to feed these people and meet the consumer needs of a developing world. With very little land remaining for agricultural expansion, they as a society need to find ways to maximize the use of their world’s resources. Plants produce a variety of rare natural products which are used in their daily lives as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals and agricultural chemicals. They strive to reduce their dependence on land- and resource-intensive practices by recreating natural processes through biotechnology.

Simprints is a nonprofit tech company committed to transforming the way the world fights poverty. We build technology to radically increase transparency and effectiveness in global development, making sure that every vaccine, every dollar, every public good reaches the people who need them most.

Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%. Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based on single-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture.

Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximize global health impact and lower overall healthcare costs.

Particles for Humanity transforms early-stage medical technology into products for people living in low-resource settings. Its development plans include a portfolio of products for improving vaccination and reducing malnutrition. Its rigorous product development process is based on end-user input and is focused on financially sustainable product opportunities.

EducationSuperHighway is a 501c(3) non-profit organization committed to upgrading every public school in the United States to a robust digital learning ready (100Mbps+) Internet connection.

BetterLesson, Inc. develops and offers a professional development platform for teachers. Its platform connects teachers to their personal coaches for setting professional development challenges and objectives, creating individualized learning plans, and making teaching strategies. It provides a searchable database to users to find lesson plans, classroom materials, and instructional resources from teachers; browse various documents, presentations, lessons, units, and courses; and share curriculum and connect with fellow educators. BetterLesson, Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

NemoCare is developing the smartest and most comprehensive patient monitoring and management system. It is an innovative, continuous vital sign data acquisition, analysis and prediction engine that combines unobtrusive wireless wearable sensors and networks, analytical algorithms and big data to provide affordable continuous, high resolution monitoring for all newborns in hospital, and at home. We use design thinking principles to build life-saving technologies that will transform the way healthcare is delivered. Our current area of work is in newborn and maternal care.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.

Code For Africa is a data journalism and civic technology initiative that operates CitizenLabs to help fast-track digital experimentation and transformation in newsrooms and other social justice organizations. It runs digital fellowships and digital skills programs. The institution also provides funding to digital journalism pioneers, through the innovateAfrica, impactAfrica, and the CfAfrica Sandbox funds. Code For Africa was founded in 2012 and is headquartered in Nairobi, Kenya.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, develops antibody and recombinant protein bio-therapeutics. The company was founded in 2016 and is based in Hangzhou, China. Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of Just Biotherapeutics, Inc. As of January 2, 2019, Hangzhou Just Biotherapeutics, Ltd. operates as a subsidiary of MabSpace Biosciences Co., Ltd..

Ilara Health brings accurate and affordable diagnostics to rural Africans through miniature, AI-powered diagnostic devices that are integrated via a proprietary technology platform and distributed directly to primary care doctors.

Enko Chem discovers and develops novel products for farmers to protect their crops from pests and diseases. Their proprietary technology platform represents a revolutionary approach to rapidly discover safe and economical solutions that are needed to ensure sustainable food production. It was founded in 2017 and headquartered in Woburn, Massachusetts.

Startup Weekend is an entrepreneurship foundation and an educational movement for entrepreneurs. It helps entrepreneurs obtain related education, launch businesses, build networks, learn skills, join global communities, save money, and more. Launched in January 2007, Startup Weekend provides an entrepreneurial business workshop within a 54-hour weekend, bringing business ideas to the stage of incorporation of an organization with its solutions.

ShopUp is a capital appraisal platform for small and micro-entrepreneurs selling on social media. It also helps social media based micro-entrepreneurs in developing countries get access to affordable financing. ShopUp was founded in 2017 and is headquartered in Dhaka, Bangladesh.

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.